文献速递糖尿病

药物靶向大麻素1型受体影响免疫细胞与胰岛的交互作用以减少人胰岛炎

Pharmaceutical targeting of the cannabinoid type 1 receptor impacts the crosstalk between immune cells and islets to reduce insulitis in humans.
PubMed 文献 · Diabetologia · 2024-06-12

研究建立模拟人胰岛炎的离体模型,发现1型糖尿病发病时循环CD4+ T细胞和胰岛β细胞中CNR1表达上调;外周限制性CB1R反向激动剂JD-5037可阻止人和小鼠胰岛炎起始,机制涉及抑制胰岛NO产生和改善未折叠蛋白反应ATF6臂,从而维持胰岛细胞活力和功能。

要点

  • 1型糖尿病发病时循环CD4+ T细胞CNR1表达较健康人上调6.9倍,分选胰岛β细胞上调3.6倍。
  • CB1R反向激动剂JD-5037阻止人和小鼠胰岛炎起始,减少胰岛细胞因子/趋化因子表达。
  • CB1R阻断防止胰岛NO产生并改善未折叠蛋白反应ATF6臂,维持胰岛细胞活力和功能。

核心结论

  • 结果提示CB1R可能是1型糖尿病的有趣靶点,并揭示了胰岛炎的调控机制。
  • 这些发现可能也适用于2型糖尿病,其中胰岛炎症也是病理生理因素。

研究设计与样本

  • 从1型糖尿病发病个体和非糖尿病个体的外周血单核细胞(PBMC)中分离CD4+ T淋巴细胞,提取RNA并通过实时PCR分析mRNA表达。
  • 通过数据挖掘获得1型糖尿病供者单β细胞表达数据。
  • 将男性和女性尸体供者的人胰岛在溶解的细胞外基质凝胶中3D培养,与同一供者PBMC共培养,并在载体或递增浓度CB1R阻断剂JD-5037存在下用细胞因子(IL-1β、TNF-α、IFN-γ)孵育24-48小时。
  • 使用CRISPR/Cas9技术敲除CNR1表达;通过活细胞探测和实时PCR检测活力、细胞内应激和信号传导;在灌流系统中测定葡萄糖刺激的胰岛素分泌;通过显微镜监测免疫细胞浸润胰岛。
  • 7周龄非肥胖糖尿病小鼠用JD-5037治疗1周后处死,通过流式细胞术分析胰岛浸润的免疫细胞。

主要发现

  • 1型糖尿病发病个体循环CD4+ T细胞中CNR1表达较健康个体上调6.9倍;1型糖尿病供者分选胰岛β细胞中CNR1表达较健康对照上调3.6倍。
  • 外周限制性CB1R反向激动剂JD-5037阻止了人和小鼠胰岛炎的起始。
  • CB1R阻断防止胰岛NO产生并改善未折叠蛋白反应ATF6臂,导致人胰岛中细胞因子/趋化因子表达降低,从而维持胰岛细胞活力和功能。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Insulitis, a hallmark of inflammation preceding autoimmune type 1 diabetes, leads to the eventual loss of functional beta cells. However, functional beta cells can persist even in the face of continuous insulitis. Despite advances in immunosuppressive treatments, maintaining functional beta cells to prevent insulitis progression and hyperglycaemia remains a challenge. The cannabinoid type 1 receptor (CB1R), present in immune cells and beta cells, regulates inflammation and beta cell function. Here, we pioneer an ex vivo model mirroring human insulitis to investigate the role of CB1R in this process. METHODS: CD4+ T lymphocytes were isolated from peripheral blood mononuclear cells (PBMCs) from male and female individuals at the onset of type 1 diabetes and from non-diabetic individuals, RNA was extracted and mRNA expression was analysed by real-time PCR. Single beta cell expression from donors with type 1 diabetes was obtained from data mining. Patient-derived human islets from male and female cadaveric donors were 3D-cultured in solubilised extracellular matrix gel in co-culture with the same donor PBMCs, and incubated with cytokines (IL-1β, TNF-α, IFN-γ) for 24-48 h in the presence of vehicle or increasing concentrations of the CB1R blocker JD-5037. Expression of CNR1 (encoding for CB1R) was ablated using CRISPR/Cas9 technology. Viability, intracellular stress and signalling were assayed by live-cell probing and real-time PCR. The islet function measured as glucose-stimulated insulin secretion was determined in a perifusion system. Infiltration of immune cells into the islets was monitored by microscopy. Non-obese diabetic mice aged 7 weeks were treated for 1 week with JD-5037, then euthanised. Profiling of immune cells infiltrated in the islets was performed by flow cytometry. RESULTS: CNR1 expression was upregulated in circulating CD4+ T cells from individuals at type 1 diabetes onset (6.9-fold higher vs healthy individuals) and in sorted islet beta cells from donors with type 1 diabetes (3.6-fold higher vs healthy counterparts). The peripherally restricted CB1R inverse agonist JD-5037 arrested the initiation of insulitis in humans and mice. Mechanistically, CB1R blockade prevented islet NO production and ameliorated the ATF6 arm of the unfolded protein response. Consequently, cyto/chemokine expression decreased in human islets, leading to sustained islet cell viability and function. CONCLUSIONS/INTERPRETATION: These results suggest that CB1R could be an interesting target for type 1 diabetes while highlighting the regulatory mechanisms of insulitis. Moreover, these findings may apply to type 2 diabetes where islet inflammation is also a pathophysiological factor. DATA AVAILABILITY: Transcriptomic analysis of sorted human beta cells are from Gene Expression Omnibus database, accession no. GSE121863, available at https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM3448161 .

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Wreven E, Ruiz de Adana MS, Hardivillé S, et al. Pharmaceutical targeting of the cannabinoid type 1 receptor impacts the crosstalk between immune cells and islets to reduce insulitis in humans. Diabetologia. 2024. PMID: 38864887. doi:10.1007/s00125-024-06193-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。